Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

20121,503 citationsJournal Articlebronze Open Access

Authors

Anas Younes · The University of Texas MD Anderson Cancer Center

Ajay K. Gopal · The University of Texas MD Anderson Cancer Center

Scott E. Smith · The University of Texas MD Anderson Cancer Center

Stephen M. Ansell · The University of Texas MD Anderson Cancer Center

Joseph D. Rosenblatt · The University of Texas MD Anderson Cancer Center

Kerry J. Savage · The University of Texas MD Anderson Cancer Center

Abstract

The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after auto-SCT. Durable CRs approaching 2 years were observed, supporting study in earlier lines of therapy.

Topics & Keywords

Lymphoma Diagnosis and Treatment Cutaneous lymphoproliferative disorders research CNS Lymphoma Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 30, Issue 18, pp. 2183-2189

DOI: 10.1200/jco.2011.38.0410

Field-Weighted Citation Impact: 89.65